Literature DB >> 8221354

Cost-effectiveness of intravenous thrombolytic drugs for acute myocardial infarction.

C D Naylor, S Bronskill, V Goel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8221354

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


× No keyword cloud information.
  6 in total

1.  Costs in Perspective: Understanding Cost-Effectiveness Analysis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 2.  Streptokinase. A pharmacoeconomic appraisal of its use in the management of acute myocardial infarction.

Authors:  J C Gillis; K L Goa
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

Review 3.  Alteplase: a pharmacoeconomic evaluation of its use in the management of myocardial infarction.

Authors:  L B Barradell; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-11       Impact factor: 4.981

4.  Economics and Quality of Life After Acute Myocardial Infarction: Insights from GUSTO-I.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 5.  Maximizing the benefits of thrombolytic therapy for acute myocardial infarction.

Authors:  J Cairns; P W Armstrong; I Belenkie; J Hirsh; D E Johnstone; M Knudtson; M Lemieux; D Massel; C D Naylor; L Roy
Journal:  CMAJ       Date:  1995-03-15       Impact factor: 8.262

6.  A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction.

Authors:  S C Kalish; J H Gurwitz; H M Krumholz; J Avorn
Journal:  J Gen Intern Med       Date:  1995-06       Impact factor: 5.128

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.